Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: TERIPARATIDE, . Treffer: 33

2019

Minisola, S; Marin, F; Kendler, DL; Geusens, P; Zerbini, CAF; Russo, LA; Casado, E; Fahrleitner-Pammer, A; Stepan, JJ; Lespessailles, E; Moericke, R; Bagur, A; Lakatos, P; López-Romero, P; Body, JJ Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Arch Osteoporos. 2019; 14(1): 10-10.
Web of Science PubMed FullText FullText_MUG

 

2018

Geusens, P; Marin, F; Kendler, DL; Russo, LA; Zerbini, CA; Minisola, S; Body, JJ; Lespessailles, E; Greenspan, SL; Bagur, A; Stepan, JJ; Lakatos, P; Casado, E; Moericke, R; López-Romero, P; Fahrleitner-Pammer, A Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
J Bone Miner Res. 2018; 33(5):783-794 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kendler, DL; Marin, F; Zerbini, CAF; Russo, LA; Greenspan, SL; Zikan, V; Bagur, A; Malouf-Sierra, J; Lakatos, P; Fahrleitner-Pammer, A; Lespessailles, E; Minisola, S; Body, JJ; Geusens, P; Moricke, R; Lopez-Romero, P Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
LANCET. 2018; 391(10117): 230-240.
Web of Science PubMed FullText FullText_MUG

 

Paschalis, EP; Krege, JH; Gamsjaeger, S; Eriksen, EF; Burr, DB; Disch, DP; Stepan, JJ; Fahrleitner-Pammer, A; Klaushofer, K; Marin, F; Pavo, I Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray-Based Bone Assessment Techniques.
J Bone Miner Res. 2018; 33(12):2230-2235
Web of Science PubMed FullText FullText_MUG

 

2017

Fahrleitner-Pammer, A; Wagner, D; Krisper, P; Amrein, K; Dimai, H Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report.
Osteoporos Int. 2017; 28(3):1149-1152 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Hohenberger, G; Schwarz, A; Hartwig, E; Bücking, B [Teriparatide as a therapy approach in sacral insufficiency fractures].
Unfallchirurg. 2017; 120(11):1000-1003 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Paschalis, EP; Gamsjaeger, S; Hassler, N; Fahrleitner-Pammer, A; Dobnig, H; Stepan, JJ; Pavo, I; Eriksen, EF; Klaushofer, K Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality.
Bone. 2017; 95(2):41-46
Web of Science PubMed FullText FullText_MUG

 

2016

Fahrleitner-Pammer, A; Burr, D; Dobnig, H; Stepan, JJ; Petto, H; Li, J; Krege, JH; Pavo, I Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.
Bone. 2016; 89(6):16-24 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Khan, AA; Morrison, A; Kendler, DL; Rizzoli, R; Hanley, DA; Felsenberg, D; McCauley, LK; O'Ryan, F; Reid, IR; Ruggiero, SL; Taguchi, A; Tetradis, S; Watts, NB; Brandi, ML; Peters, E; Guise, T; Eastell, R; Cheung, AM; Morin, SN; Masri, B; Cooper, C; Morgan, SL; Obermayer-Pietsch, B; Langdahl, BL; Dabagh, RA; Davison, KS; Sándor, GK; Josse, RG; Bhandari, M; El Rabbany, M; Pierroz, DD; Sulimani, R; Saunders, DP; Brown, JP; Compston, J; International Task Force on Osteonecrosis of the Jaw Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
J Clin Densitom. 2016; 20(1):8-24
Web of Science PubMed FullText FullText_MUG

 

Svejda, B; Muschitz, Ch; Gruber, R; Brandtner, Ch; Svejda, Ch; Gasser, RW; Santler, G; Dimai, HP [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Wien Med Wochenschr. 2016; 166(1-2):68-74 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Khan, AA; Morrison, A; Hanley, DA; Felsenberg, D; McCauley, LK; O'Ryan, F; Reid, IR; Ruggiero, SL; Taguchi, A; Tetradis, S; Watts, NB; Brandi, ML; Peters, E; Guise, T; Eastell, R; Cheung, AM; Morin, SN; Masri, B; Cooper, C; Morgan, SL; Obermayer-Pietsch, B; Langdahl, BL; Al Dabagh, R; Davison, KS; Kendler, DL; Sándor, GK; Josse, RG; Bhandari, M; El Rabbany, M; Pierroz, DD; Sulimani, R; Saunders, DP; Brown, JP; Compston, J; International Task Force on Osteonecrosis of the Jaw Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
J Bone Miner Res. 2015; 30(1): 3-23. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Hofstetter, B; Gamsjaeger, S; Varga, F; Dobnig, H; Stepan, JJ; Petto, H; Pavo, I; Klaushofer, K; Paschalis, EP Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
Osteoporos Int. 2014; 25(12):2709-2719
Web of Science PubMed FullText FullText_MUG

 

Ma, YL; Zeng, QQ; Chiang, AY; Burr, D; Li, J; Dobnig, H; Fahrleitner-Pammer, A; Michalská, D; Marin, F; Pavo, I; Stepan, JJ Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.
Bone. 2014; 59(5):139-147
Web of Science PubMed FullText FullText_MUG

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Pavo, I; Haschka, J; Schima, W; Kapiotis, S; Resch, H Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
J Bone Miner Res. 2014; 29(8):1777-1785 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Ljunggren, Ö; Barrett, A; Stoykov, I; Langdahl, BL; Lems, WF; Walsh, JB; Fahrleitner-Pammer, A; Rajzbaum, G; Jakob, F; Karras, D; Marin, F Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study.
BMC Musculoskelet Disord. 2013; 14(8):251-251 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Lung, S; Resch, H Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
J Bone Miner Res. 2013; 28(1):196-205 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Jakob, F; Oertel, H; Langdahl, B; Ljunggren, O; Barrett, A; Karras, D; Walsh, JB; Fahrleitner-Pammer, A; Rajzbaum, G; Barker, C; Lems, WF; Marin, F Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study.
Eur J Endocrinol. 2012; 166(1):87-97 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Karras, D; Stoykov, I; Lems, WF; Langdahl, BL; Ljunggren, ; Barrett, A; Walsh, JB; Fahrleitner-Pammer, A; Rajzbaum, G; Jakob, F; Marin, F Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
J Rheumatol. 2012; 39(3):600-609
Web of Science PubMed FullText FullText_MUG

 

Walsh, JB; Lems, WF; Karras, D; Langdahl, BL; Ljunggren, O; Fahrleitner-Pammer, A; Barrett, A; Rajzbaum, G; Jakob, F; Marin, F Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS).
Calcif Tissue Int. 2012; 90(5):373-383 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2011

Fahrleitner-Pammer, A; Langdahl, BL; Marin, F; Jakob, F; Karras, D; Barrett, A; Ljunggren, O; Walsh, JB; Rajzbaum, G; Barker, C; Lems, WF Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
Osteoporos Int. 2011; 22(10): 2709-2719. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2010

Satterwhite, J; Heathman, M; Miller, PD; Marín, F; Glass, EV; Dobnig, H Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis.
Calcif Tissue Int. 2010; 87(6):485-492 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Stepan, JJ; Burr, DB; Li, J; Ma, YL; Petto, H; Sipos, A; Dobnig, H; Fahrleitner-Pammer, A; Michalská, D; Pavo, I Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
Osteoporos Int. 2010; 21(12): 2027-2036.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2009

Dimai, HP; Pietschmann, P; Resch, H; Preisinger, E; Fahrleitner-Pammer, A; Dobnig, H; Klaushofer, K; Austrian Society for Bone and Mineral Research (AuSBMR) Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009
Wien Med Wochenschr Suppl. 2009; (122): 1-34.
PubMed FullText FullText_MUG Google Scholar

 

Dobnig, H; Stepan, JJ; Burr, DB; Li, J; Michalská, D; Sipos, A; Petto, H; Fahrleitner-Pammer, A; Pavo, I Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated With Alendronate *
J Bone Miner Res. 2009; 24(12): 1998-2006. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Eastell, R; Nickelsen, T; Marin, F; Barker, C; Hadji, P; Farrerons, J; Audran, M; Boonen, S; Brixen, K; Gomes, JM; Obermayer-Pietsch, B; Avramidis, A; Sigurdsson, G; Gluer, CC Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)
J BONE MINER RES 2009; 24(4):726-736.-28th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research; SEP 15-19, 2006; Philadelphia, PA. [Oral Communication]

 

Eastell, R; Nickelsen, T; Marin, F; Barker, C; Hadji, P; Farrerons, J; Audran, M; Boonen, S; Brixen, K; Gomes, JM; Obermayer-Pietsch, B; Avramidis, A; Sigurdsson, G; Glüer, CC Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
J Bone Miner Res. 2009; 24(4): 726-736. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Langdahl, BL; Marin, F; Shane, E; Dobnig, H; Zanchetta, JR; Maricic, M; Krohn, K; See, K; Warner, MR Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status
OSTEOPOROSIS INT. 2009; 20(12): 2095-2104.
Web of Science Google Scholar

 

Langdahl, BL; Rajzbaum, G; Jakob, F; Karras, D; Ljunggren, O; Lems, WF; Fahrleitner-Pammer, A; Bernard Walsh, J; Barker, C; Kutahov, A; Marin, F Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Postmenopausal Women Treated with Teriparatide: 18-Month Data from the European Forsteo Observational Study (EFOS).
Calcif Tissue Int. 2009; 85(6): 484-493. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2008

Boonen, S; Marin, F; Obermayer-Pietsch, B; Simões, ME; Barker, C; Glass, EV; Hadji, P; Lyritis, G; Oertel, H; Nickelsen, T; McCloskey, EV; for the EUROFORS Investigators Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
J Clin Endocrinol Metab. 2008; 93(3):852-860 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Minne, H; Audran, M; Simões, ME; Obermayer-Pietsch, B; Sigurðsson, G; Marín, F; Dalsky, GP; Nickelsen, T; EUROFORS Study Group Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
Curr Med Res Opin. 2008; 24(11):3117-3128 [Keynote lecture]
Web of Science PubMed FullText FullText_MUG

 

Obermayer-Pietsch, BM; Marin, F; McCloskey, EV; Hadji, P; Farrerons, J; Boonen, S; Audran, M; Barker, C; Anastasilakis, AD; Fraser, WD; Nickelsen, T Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.
J BONE MINER RES. 2008; 23(10): 1591-1600. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Rajzbaum, G; Jakob, F; Karras, D; Ljunggren, O; Lems, WF; Langdahl, BL; Fahrleitner-Pammer, A; Walsh, JB; Gibson, A; Tynan, AJ; Marin, F Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting.
Curr Med Res Opin. 2008; 24(2): 377-384.
Web of Science PubMed FullText FullText_MUG

 

2004

Dobnig, H A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
EXPERT OPIN PHARMACOTHER. 2004; 5(5): 1153-1162.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

© Meduni Graz Impressum